OPKO Health and Entera Bio abstract selected for ESPEN Congress

OPKO Health Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) announced that their research abstract on an oral GLP-2 tablet for short bowel syndrome treatment has been selected for presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress in Prague, Czech Republic, September 13-16, 2025.

The abstract, titled "First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome," will be presented as a poster on September 13, 2025, from 3:30-4:00 p.m. local time in Forum Hall Foyer 3.

The oral GLP-2 tablet program combines OPKO's proprietary long-acting GLP-2 agonist with Entera's N-Tab technology for patients with short bowel syndrome and related gastrointestinal disorders. The current approved GLP-2 agonist, marketed as GATTEX (teduglutide), requires daily subcutaneous injections.

"Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration," said Miranda Toledano, Entera's Chief Executive Officer.

Short bowel syndrome is a rare malabsorptive condition caused by significant loss of functional or physical bowel mass. Approximately 30,000 patients across the US and EU live with the condition, according to the press release. Current annual sales of GATTEX, the only approved therapy for short bowel syndrome, total approximately $800 million.

The condition reduces patients' ability to absorb nutrients and fluids, putting them at risk of malnutrition and unintended weight loss. Short bowel syndrome accounts for approximately 75% of chronic intestinal failure cases in adults and 50% in children.

You May Also Be Interested In

• RBC Capital Starts Natera (NTRA) at Outperform
• Adobe CFO Dan Durn to depart company in June 2026
• Western Midstream completes $1.6 billion Brazos Delaware acquisition